



society of hematologic oncology

PROGRAMME

1^{ère} édition

16-18 Novembre 2022

Sorbonne Université
Campus Pierre et Marie Curie
PARIS

En association avec



society of hematologic oncology

COMITÉ SCIENTIFIQUE

- **Mauricette MICHALLET** (*Présidente, Hématologue, Centre Léon Bérard, Lyon*)
- **Amine BELHABRI** (*Hématologue, Centre Léon Bérard, Lyon*)
- **Sylvain CHOQUET** (*Hématologue, Hôpital Pitié-Salpêtrière, Paris*)
- **Florence CYMBALISTA** (*Hématologue, Hôpital Avicenne, Bobigny*)
- **Roch HOUOT** (*Hématologue, Centre Hospitalier Universitaire de Rennes, Rennes*)
- **Jean-Jacques KILADJIAN** (*Hématologue, Hôpital Saint-Louis, Paris*)
- **Xavier LELEU** (*Hématologue, Centre Hospitalier Universitaire de Poitiers, Poitiers*)
- **François-Xavier MAHON** (*Hématologue, Institut Bergonié, Bordeaux*)
- **Anne-Sophie MICHALLET** (*Hématologue, Centre Léon Bérard, Lyon*)
- **Franck NICOLINI** (*Hématologue, Centre Léon Bérard, Lyon*)
- **Sophie PARK** (*Hématologue, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble*)
- **Christian RECHER** (*Hématologue, Institut Universitaire du Cancer de Toulouse, Toulouse*)
- **Philippe ROUSSELOT** (*Hématologue, Centre Hospitalier de Versailles, Versailles*)











PRELIMINARY PROGRAMME

Wednesday 16th November 2022

	Time / Language
<p>1:30 p.m. <i>Opening</i></p>	
<p>2:00 – 2:30 p.m. <i>Introduction</i></p>	
<p>2:30 – 3:30 p.m. <i>Session 1: Chronic Myeloid Leukemia</i></p> <p>Chair: Franck NICOLINI (Hematology, Léon Bérard Center, Lyon)</p> <ul style="list-style-type: none"> • ASCIMINIB (Allosteric Inhibitor): A new step of treatment of CML - Delphine REA (<i>Hematology, University Hospital of Paris, Paris</i>) • STOP ITK: French Experience - François-Xavier MAHON (<i>Hematology, Bergonié Institute, Bordeaux</i>) • Re-emergence of INTERFERON in CML - Franck NICOLINI (<i>Hematology, Léon Bérard Center, Lyon</i>) 	<p>20 min </p> <p>20 min </p> <p>20 min </p>
<p>3:30 – 4:00 p.m. ☕ BREAK</p>	
<p>4:00 – 5:20 p.m. <i>Session 2: Chronic Lymphocytic Leukemia</i></p> <p>Chair: Florence CYMBALISTA (Hematology, Avicenne Hospital, Bobigny)</p> <ul style="list-style-type: none"> • Is MRD ready for prime time? - Rémi LETESTU (<i>Biological Hematology, Paris-Seine-Saint-Denis University Hospitals, Bobigny</i>) • Adverse events and resistance to targeted agents - Anne QUINQUENEL (<i>Hematology, University Hospital of Reims, Reims</i>) • Future of CLL treatment - Susan O'BRIEN (<i>Hematology, Oncology, Internal Medecin, MD Anderson Cancer Center, Orange L.A</i>) <p>Debate : Continuous versus time limited treatment</p> <p>Continuous treatment - Alain DELMER (<i>Hematology, University Hospital of Reims, Reims</i>)</p> <p>VS</p> <p>Time limited treatment - Anne-Sophie MICHALLET (<i>Hematology, Léon Bérard Center, Lyon</i>)</p>	<p>20 min </p> <p>20 min </p> <p>20 min </p> <p>20 min </p>
<p>5:20 – 6:20 p.m. <i>Session 3: Myeloproliferative Neoplasms</i></p> <p>Chair: Jean-Jacques KILADJIAN (Hematology, Saint-Louis Hospital, Paris)</p> <ul style="list-style-type: none"> • Deciphering TP53 mutant Cancer Evolution with Single-Cell Multi-Omics - Adam MEAD (<i>Hematology, Oncology, University of Oxford, Oxford</i>) • Update in the treatment of Polycythemia vera - Jean-Jacques KILADJIAN (<i>Hematology, Saint-Louis Hospital, Paris</i>) <p>Debate: Myelofibrosis: Strategy after resistance to RUXOLUTINIB</p> <p>Place and timing of Allogeneic HCT - Marie ROBIN (<i>Hematology, Saint-Louis Hospital, Paris</i>)</p> <p>VS</p> <p>Second line therapy in case of ineligibility to Allogeneic HCT - Lydia ROY (<i>Hematology, Henri-Mondor Hospital, Paris</i>)</p>	<p>20 min </p> <p>20 min </p> <p>20 min </p>
<p>6:20 – 6:50 p.m. <i>Oral Presentations I</i> (selected oral presentations by the scientific committee)</p>	<p>30 min </p>

Thursday 17th November 2022

		Time / Language
7:30 a.m.	Opening	
8:00 – 9:20 a.m.	Session 4: Myelodysplastic Syndromes	
	Chairs: Sophie PARK (Hematology, University Hospital of Grenoble Alpes, Grenoble) Pierre FENAUX (Hematology, Saint-Louis Hospital, Paris)	
	• State-of-the-Art in low-risk myelodysplasia - Sophie PARK (Hematology, University Hospital of Grenoble Alpes, Grenoble)	20 min 
	• State-of-the-Art in high-risk myelodysplasia - Thomas CLUZEAU (Hematology, University Hospital of Nice, Nice)	20 min 
	• Which therapeutic target in chronic myelomonocytic leukemia? - Eric SOLARY (Hematology, Gustave Roussy Center, Paris)	20 min 
	• Current advances in myelodysplastic syndromes with SF3B1 mutations - Michaela FONTENAY (Biological Hematology, Cochin Institute, Paris)	20 min 
9:20 – 9:50 a.m.	 BREAK	
9:50 - 11:10 a.m.	Session 5: Acute Lymphoblastic Leukemia	
	Chair: Philippe ROUSSELOT (Hematology, Hospital of Versailles, Versailles)	
	• Chemofree regimens in Ph+ ALL - Sabina CHIARETTI (Cellular Biotechnology, Hematology, Hematology Sapienza University, Rome)	20 min 
	• How much chemotherapy with TKI in Ph+ ALL? - Philippe ROUSSELOT (Hematology, Hospital of Versailles, Versailles)	20 min 
	• Recent advances in adults ALL - Hagop KANTARJIAN (Oncology, Hematology, University of Texas MD Anderson Cancer Center, Austin)	20 min 
	• Targeting T cell signaling in T-ALL - Ludovic LHERMITTE (Biological Hematology, Necker-Enfants Malades Hospital, Paris)	20 min 
11:10 – 11:30 a.m.	Oral Presentations II (selected oral presentations by the scientific committee)	20 min 
11:30 a.m – 1:00 p.m	Symposium	
1:00 – 2:00 p.m	 BREAK	
2:00 – 3:20 p.m.	Session 6: Acute Myeloid Leukemia	
	Chairs: Norbert VEY (Hematology, Paoli-Calmettes Institute, Marseille) Arnaud PIGNEUX (Hematology, University Hospital of Bordeaux, Bordeaux)	
	• New strategies for treatment of AML (except anti-IDH and Immunotherapy) - Naval G. DAVER (Hematology, MD Anderson Cancer Center, Houston)	20 min 
	• Management of IDH mutated AML - Stéphane de BOTTON (Hematology, Gustave Roussy Center, Villejuif)	20 min 
	• Diagnosis and prognosis prediction: NGS, MRD, Artificial Intelligence - Torsten HAFERLACH (Oncology Hematology, MLL Munich Leukemia Laboratory GmbH, Munich)	20 min 
	Debate Chair: Christian RECHER (Hematology, University Cancer Institute of Toulouse, Toulouse)	
	Intensive chemotherapy - Lionel ADÈS (Hematology, Saint-Louis Hospital, Paris) VS Non Intensive Chemotherapy in « fit » patients - Nigel RUSSELL (Hematology, Norfolk House Medical Centre, Nottingham)	20 min 

	Session 7: Lymphomas	Time / Language
3:20 – 4:40 p.m.	Chair: Sylvain CHOQUET (Hematology, Pitié-Salpêtrière Hospital, Paris)	
	• Circulating Tumour DNA and Lymphoma - Fabrice JARDIN (<i>Hematology, Henri Becquerel Center, Rouen</i>)	20 min 
	• The Future of Bispecific Antibodies in Lymphoma - Guillaume CARTRON (<i>Hematology, University Hospital of Montpellier, Montpellier</i>)	20 min 
	• The Future of Autologous Hematopoietic Cell Transplantation in Aggressive B Lymphomas - Catherine THIEBLEMONT (<i>Hematology, Saint-Louis Hospital, Paris</i>)	20 min 
	• State-of-the-Art in Peripheral T-cell Lymphomas - David SIBON (<i>Hematology, Necker-Enfants Malades Hospital, Paris</i>)	20 min 
4:40 – 5:10 p.m.	 BREAK	
5:10 – 6:30 p.m.	Session 8: Multiple Myeloma	
	Chair: Xavier LELEU (Hematology, University Hospital of Poitiers, Poitiers)	
	• NGS and Myeloma: Role in Prognosis and Minimal Residual Disease - Hervé AVET-LOISEAU (<i>Hematology, University Institute of Toulouse, Toulouse</i>)	20 min 
	• First Line in Multiple Myeloma: What is going to change? - Cyrille TOUZEAU (<i>Hematology, University Hospital of Nantes, Nantes</i>)	20 min 
	• Relapse in Multiple Myeloma: How to prolong Survival? - Mohamad MOHTY (<i>Hematology, Saint-Antoine Hospital, Paris</i>)	20 min 
	• Immunotherapy in Multiple Myeloma: From now to tomorrow - Salomon MANIER (<i>Hematology, University Hospital of Lille, Lille</i>)	20 min 
6:30 – 6:50 p.m.	Oral Presentations III <i>(selected oral presentations by the scientific committee)</i>	20 min 

Friday 18th November 2022

7:30 a.m.	Opening	
8:00 – 9:20 a.m.	Session 9: CART cells	
	Chair: Roch HOUOT (Hematology, University Hospital of Rennes, Rennes)	
	• Update of CART cells activity in Lymphoma - Roch HOUOT (<i>Hematology, University Hospital of Rennes, Rennes</i>)	20 min 
	• Update of CART cells activity in Acute Lymphoblastic Leukemia - Nicolas BOISSEL (<i>Hematology, Saint-Louis Hospital, Paris</i>)	20 min 
	• Update of CART cells activity in Myeloma - Philippe MOREAU (<i>Hematology, University Hospital of Nantes, Nantes</i>)	20 min 
	• Overview and perspectives of CART cells activities in France and in Europe - Christian CHABANNON (<i>Oncology, Paoli-Calmettes Institute, Marseille</i>)	20 min 
9:20 – 9:50 a.m.	Discussion:	30 min 
	Bispecific antibodies and CART cells: Which strategy to choose? When? And for whom? (NHL, Myeloma and ALL) - Roch HOUOT (<i>Hematology, University Hospital of Rennes, Rennes</i>), Nicolas BOISSEL (<i>Hematology, Saint-Louis Hospital, Paris</i>), Philippe MOREAU (<i>Hematology, University Hospital of Nantes, Nantes</i>), Guillaume CARTRON (<i>Hematology, University Hospital of Montpellier, Montpellier</i>), Salomon MANIER (<i>Hematology, University Hospital of Lille, Lille</i>) & Philippe ROUSSELOT (<i>Hematology, Hospital of Versailles, Versailles</i>)	
9:50 – 10:50 a.m.	Symposium	
10:50 – 11:20 a.m.	 BREAK	
11:20 a.m. – 12:20 p.m.	Innovation patients	
12:20 – 1:20 p.m.	Closing Remarks	